Table 1 Clinical characteristics of patients

Age

0.085

 ≤ 65 years

25 (73.5%)

20 (83.3%)

5 (50.0%)

 > 65 years

9 (26.5%)

4 (16.7%)

5 (50.0%)

 Median (IQR)

59 (52–67)

56 (52–61)

66 (57–69)

Sex

 > 0.999

 Female

10 (29.4%)

7 (29.2%)

3 (30.0%)

 Male

24 (70.6%)

17 (70.8%)

7 (70.0%)

Ann Arbor stage

 > 0.999

 II

1 (2.9%)

1 (4.2%)

0 (0%)

 III

1 (2.9%)

1 (4.2%)

0 (0%)

 IV

32 (94.1%)

22 (91.7%)

10 (100%)

Histologic subtype

0.157

 Classic

27 (79.4%)

21 (87.5%)

6 (60.0%)

 Blastoid

7 (20.6%)

3 (12.5%)

4 (40.0%)

B symptoms

0.067

 Yes

4 (11.8%)

1 (4.2%)

3 (30.0%)

 No

30 (88.2%)

23 (95.8%)

7 (70.0%)

Ki-67 expression

0.437

 < 30%

11 (32.4%)

9 (37.5%)

2 (20.0%)

 ≥ 30%

23 (67.6%)

15 (62.5%)

8 (80.0%)

MIPI

0.002**

 Low

21 (61.8%)

19 (79.2%)

2 (20.0%)

 Intermediate

8 (23.5%)

4 (16.7%)

4 (40.0%)

 High

5 (14.7%)

1 (4.2%)

4 (40.0%)

MIPI-c

0.004**

 Low

9 (26.5%)

8 (33.3%)

1 (10.0%)

 Low-moderate

13 (38.2%)

12 (50.0%)

1 (10.0%)

 Moderate-high

8 (23.5%)

3 (12.5%)

5 (50.0%)

 High

4 (11.8%)

1 (4.2%)

3 (30.0%)

Extranodal involvement

 > 0.999

 Yes

32 (94.1%)

2 (8.3%)

0 (0%)

 No

2 (5.9%)

22 (91.7%

10 (100%)

Chemotherapy regimen

0.077

 R-CHOP

10 (29.4%)

4 (16.7%)

6 (60.0%)

 R-CHOP/DHAP

17 (50.0%)

13 (54.2%)

4 (40.0%)

 R-CHOP/BAC

1 (2.9%)

1 (4.2%)

0 (0%)

 R-DA-EPOCH/DHAP

1 (2.9%)

1 (4.2%)

0 (0%)

 BR

5 (14.7%)

5 (20.8%)

0 (0%)

Best overall response

 ~ 

 CR

24 (70.6%)

24 (100%)

0 (0%)

 PR

5 (14.7%)

0 (0%)

5 (50.0%)

 SD

2 (5.9%)

0 (0%)

2 (20.0%)

 PD

3 (8.8%)

0 (0%)

3 (30.0%)

ASCT

0.291

 Yes

5 (14.7%)

5 (20.8%)

0 (0%)

 No

29 (85.3%)

19 (79.2%)

10 (100%)

Maintenance therapy

0.005**

 Yes

23 (67.6%)

20 (83.3%)

3 (30.0%)

 No

11 (32.4%)

4 (16.7%)

7 (70.0%)

LDH (U/L)

0.037*

 Median (IQR)

191.1 (160.6–231.3)

177.5 (158.7–213.0)

229.5 (194.3–325.5)

β2-microglobulin (mg/L)^a

0.016*

 Median (IQR)

3.24 (2.53–4.29)

3.03 (2.30–3.61)

4.46 (3.36–5.78)